InnovaRx Innova Health Strategies

E22.1

Hyperprolactinemia

Billable FY2026 2025-10-01 → 2026-09-30
Exclusions 8 never code together
E22code
Excludes1
  • Cushing's syndrome (E24.-)E24.-
  • Nelson's syndrome (E24.1)E24.1
  • overproduction of ACTH not associated with Cushing's disease (E27.0)E27.0
  • overproduction of pituitary ACTH (E24.0)E24.0
  • overproduction of thyroid-stimulating hormone (E05.8-)E05.8-
E20-E35block
Excludes1
  • galactorrhea (N64.3)N64.3
  • gynecomastia (N62)N62
E00-E89chapter
Excludes1
  • transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 2
E22.1code
Use additional code
  • code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)T36-T50T36-T50
E00-E89chapter
Notes
  • All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8E07.0E16-E31E34.-
Index entries leading here 1
  • Hyperprolactinemia E22.1
Alongside this code 4 same parent — E22
Medications 1

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references
AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC23 ESRD21HCC23 ESRD24HCC23 RX08HCC43

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable
yes
Code set
FY2026
Parent
E22
Block
E20-E35
Siblings
4

Present FY2024–FY2027.